title: Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation.
abstract: Sinonasal teratocarcinosarcoma (SNTCS) is a rare and highly malignant tumour with combined features of a teratoma and carcinosarcoma. We report the first case of a SNTCS in 23 year old male treated with neo-adjuvant chemotherapy followed by cranio-facial resection. The resection specimen displayed cellular maturation in the neuroectodermal component. The patient presented with a short history of nasal obstruction, epistaxis and headache. On imaging, a bone destroying lesion of left paranasal sinuses and nasal cavity was identified. The diagnosis of SNTCS could be offered only on the third biopsy which showed heterogeneous admixture of primitive neuroectodermal, epithelial and mesenchymal elements. An adequate sampling with high index of suspicion is needed to catch hold this rare tumor. Tumor was excised after 4 cycles of neo-adjuvant chemotherapy. On microscopic examination, it showed similar epithelial and mesenchymal components as the pretreatment biopsies. However, the primitive neuroectodermal component displayed extensive neuronal maturation. The undifferentiated neuroectodermal cells were completely absent in the post chemotherapy specimen. This case throws light on the morphologic evidence of chemotherapy induced maturation in the neuroectodermal component within SNTCS, an event hitherto not reported in the literature in case of SNTCS.
authors.affiliation: Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India. drsvkane@gmail.com
authors.forename: Shubhada V
authors.initials: SV
authors.lastname: Kane
authors.forename: Arti A
authors.initials: AA
authors.lastname: Karpate
authors.forename: Munita
authors.initials: M
authors.lastname: Bal
authors.forename: S L
authors.initials: SL
authors.lastname: Juvekar
authors.forename: Prathmesh S
authors.initials: PS
authors.lastname: Pai
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002296:Carcinosarcoma / Q000473:pathology* / Q000628:therapy; D002454:Cell Differentiation / Q000187:drug effects*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009474:Neurons / Q000187:drug effects / Q000473:pathology*; D009669:Nose Neoplasms / Q000473:pathology* / Q000628:therapy; D013517:Otorhinolaryngologic Surgical Procedures; D011878:Radiotherapy; D018243:Teratocarcinoma / Q000473:pathology* / Q000628:therapy; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D004317:Doxorubicin; D002945:Cisplatin